Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 16, 2021updated 07 Jan 2022 7:09am

GeoVax commences dosing in Covid-19 booster shot trial

Through a licence agreement signed last month, GeoVax obtained global rights to the vaccine patents.

GeoVax Labs has commenced subject dosing in the Phase II segment of its Phase I/II clinical trial to analyse the potential of experimental Covid-19 vaccine, COH04S1, as a universal booster.

Developed at the City of Hope Medical Center, COH04S1 is a synthetic, attenuated modified vaccinia Ankara (sMVA) vector expressing the SARS-CoV-2 virus’ spike (S) and nucleocapsid (N) antigens.

Under an exclusive licence agreement signed last month, the company obtained global rights to the vaccine patents, as well as develop and market it in City of Hope.

The booster could be used following vaccination with vaccines approved by the US Food and Drug Administration (FDA).

Carried out at City of Hope, the Phase I/II dose-escalation trial is designed to analyse the safety and will identify the biologically effective dose of the vaccine for administration.

The Phase I segment is currently in the follow-up stage with trial results anticipated to be reported early next year.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The Phase II trial will enrol 60 healthy adult subjects aged 18 years and above, who have already received an FDA-approved Covid-19 vaccine.

This dose-escalation trial will assess the safety and immunogenicity of COH04S1 when given as a booster.

The Covid-19 neutralising antibody levels against various viral variants of concern, including the Omicron variant, and specific T-cell responses will also be analysed in the trial.

GeoVax chief scientific officer Mark Newman said: “We believe that the COH04S1 vaccine, when administered as a heterologous booster, targeting both the S and N proteins, will provide additional beneficial elements for immune system recognition versus a homologous boost using a vaccine based solely on the SARS-CoV-2 S protein.

“The COH04S1 vaccine’s MVA backbone should also be more effective at inducing SARS-CoV-2 cellular immunity, since MVA strongly induces T cell responses, even in immunocompromised individuals.”

Last month, Clover Biopharmaceuticals started a Phase II clinical trial for evaluating SCB-2019 (CpG 1018/Alum), its vaccine candidate for Covid-19, as a heterologous booster shot in individuals who received an initial vaccine regimen.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU